Huntleigh Advisors Inc. Makes New Investment in Tempus AI, Inc. (NASDAQ:TEM)

Huntleigh Advisors Inc. bought a new position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm bought 8,385 shares of the company's stock, valued at approximately $404,000.

Other institutional investors have also modified their holdings of the company. Operose Advisors LLC purchased a new position in Tempus AI in the fourth quarter worth approximately $25,000. Cherry Tree Wealth Management LLC acquired a new stake in shares of Tempus AI during the 1st quarter worth about $31,000. Farther Finance Advisors LLC purchased a new stake in Tempus AI in the 4th quarter valued at about $34,000. Prestige Wealth Management Group LLC lifted its position in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after buying an additional 965 shares during the last quarter. Finally, Continuum Advisory LLC acquired a new position in Tempus AI in the first quarter valued at about $39,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Insider Buying and Selling

In related news, Director Theodore Leonsis sold 205,847 shares of the business's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $67.66, for a total value of $13,927,608.02. Following the sale, the director directly owned 15,511 shares in the company, valued at $1,049,474.26. The trade was a 92.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James William Rogers sold 23,121 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $63.27, for a total transaction of $1,462,865.67. Following the completion of the sale, the chief financial officer owned 146,001 shares in the company, valued at $9,237,483.27. This represents a 13.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 607,522 shares of company stock worth $41,300,238 in the last ninety days. Insiders own 27.60% of the company's stock.

Tempus AI Stock Performance

Shares of TEM traded up $1.47 during mid-day trading on Friday, reaching $60.65. 6,389,112 shares of the company's stock were exchanged, compared to its average volume of 7,421,123. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.71 and a quick ratio of 1.56. The stock has a market capitalization of $10.50 billion and a PE ratio of -7.78. The business's fifty day simple moving average is $62.53 and its 200-day simple moving average is $54.27. Tempus AI, Inc. has a 52-week low of $30.81 and a 52-week high of $91.45.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.03. The business had revenue of $255.74 million for the quarter, compared to analyst estimates of $248.13 million. Tempus AI had a negative net margin of 88.27% and a negative return on equity of 533.21%. The firm's revenue for the quarter was up 75.4% on a year-over-year basis. On average, equities research analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Wall Street Analyst Weigh In

TEM has been the topic of a number of recent analyst reports. Guggenheim upped their target price on shares of Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, June 30th. BTIG Research initiated coverage on shares of Tempus AI in a research report on Monday, April 21st. They issued a "buy" rating and a $60.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $70.00 target price on shares of Tempus AI in a research report on Wednesday, May 7th. Morgan Stanley increased their price target on shares of Tempus AI from $60.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Finally, Piper Sandler raised their target price on shares of Tempus AI from $55.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, May 15th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $63.67.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.